These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8787797)

  • 1. Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients.
    Mizutani Y; Okada Y; Ogawa M; Hasegawa T; Nabeshima T
    Biol Pharm Bull; 1995 Dec; 18(12):1729-37. PubMed ID: 8787797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
    Hammerstad JP; Woodward WR; Nutt JG; Gancher ST; Block GA; Cyhan G
    Clin Neuropharmacol; 1994 Oct; 17(5):429-34. PubMed ID: 9316692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
    Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
    J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
    Othman AA; Dutta S
    Br J Clin Pharmacol; 2014 Jul; 78(1):94-105. PubMed ID: 24433449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
    Deleu D; Jacques M; Michotte Y; Ebinger G
    Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation.
    Jorga K; Fotteler B; Sedek G; Nielsen T; Aitken J
    J Neurol; 1998 Apr; 245(4):223-30. PubMed ID: 9591224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients.
    Senek M; Nyholm D; Nielsen EI
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1299-1307. PubMed ID: 29882153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
    Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
    Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV; Hoff J; Mouradian MM; Chase TN
    Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.
    Nyholm D; Askmark H; Gomes-Trolin C; Knutson T; Lennernäs H; Nyström C; Aquilonius SM
    Clin Neuropharmacol; 2003; 26(3):156-63. PubMed ID: 12782919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2020 May; 16(5):403-414. PubMed ID: 32238065
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
    Kuoppamäki M; Korpela K; Marttila R; Kaasinen V; Hartikainen P; Lyytinen J; Kaakkola S; Hänninen J; Löyttyniemi E; Kailajärvi M; Ruokoniemi P; Ellmén J
    Eur J Clin Pharmacol; 2009 May; 65(5):443-55. PubMed ID: 19229530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
    Benetello P; Furlanut M; Zara G; Baraldo M; Hassan E
    Eur Neurol; 1993; 33(1):69-73. PubMed ID: 8440292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
    Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations.
    Juncos JL; Fabbrini G; Mouradian MM; Chase TN
    Arch Neurol; 1987 Oct; 44(10):1010-2. PubMed ID: 3632371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.